ChromoTek introduces novel real-time cell cycle assay for HCA screening
Fluorescent Chromobodies® allow dynamic targeting and tracing of endogenous marker molecules in live cells and represent a versatile tool for cell biologists to monitor multiple parameters defining cellular pathways
(PresseBox) - 04.2011 - ChromoTek, a company specializing in bioimaging reagents, has launched the U2OS Cell Cycle Chromobody®, the first real-time HCA screening assay to monitor the complete cell cycle in live cells. The intracellular expression of the fluorescent Cell Cycle Chromobody® enables scientists to simultaneously analyze a set of different cellular parameters: cell size and morphology, nuclear morphology, progression of S phase (early - mid - late stage) and mitosis. This powerful assay enables screening of compounds such as cancer drugs for effects on the cell cycle and toxicity in one experiment. The U2OS Cell Cycle Chromobody® can be applied in early drug development and validation as well as in basic research.
The U2OS Cell Cycle Chromobody® is a cell line stably expressing a small binding protein which targets and traces an endogenous cell cycle marker protein. In contrast to widely used fluorescent fusion proteins, the Cell Cycle Chromobody® provides information about the distribution and dynamics of the native factor. In addition, the Cell Cycle Chromobody® is not cytotoxic and does not affect normal cell function making it an ideal tool for the analysis of molecular processes in the cell in response to external factors such as drug candidates.
With the Cell Cycle Chromobody® ChromoTek introduces a product line for cell scientists who want to analyze cellular processes in real time and to detect dynamic protein-protein interactions in biomedical research and pharmaceutical compound screening. Further Chromobody products addressing other essential cellular pathways will follow soon.
ChromoTek is a German bioimaging company located in Martinsried, the heart of the biotech cluster of the Greater Munich Area. Founded in 2008, ChromoTek services more than 1,300 customers worldwide with research reagents for cell biology and proteomics such as the GFP-Trap®, the RFP-Trap® or the GFP-Booster. ChromoTek is continuously extending its product portfolio and provides research services to leading pharma companies.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
ChromoTek is a German bioimaging company located in Martinsried, the heart of the biotech cluster of the Greater Munich Area. Founded in 2008, ChromoTek services more than 1,300 customers worldwide with research reagents for cell biology and proteomics such as the GFP-Trap®, the RFP-Trap® or the GFP-Booster. ChromoTek is continuously extending its product portfolio and provides research services to leading pharma companies.
Datum: 15.04.2011 - 11:56 Uhr
Sprache: Deutsch
News-ID 1022904
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Martinsried
Phone:
Kategorie:
Handcrafts
Anmerkungen:
Diese Pressemitteilung wurde bisher 369 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ChromoTek introduces novel real-time cell cycle assay for HCA screening
"
steht unter der journalistisch-redaktionellen Verantwortung von
ChromoTek GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
